Senate Bill Blocks Federal Penalties for Cannabis Insurance Providers

Federal Regulators Barred from Enforcement Action

The bill explicitly prohibits federal agencies from denying, revoking, or suspending licenses, imposing fines, or otherwise penalizing insurers that cover cannabis businesses operating legally under state law. It applies to all federal banking and insurance regulators, including the Office of the Comptroller of the Currency, the Federal Deposit Insurance Corporation, and state-chartered insurance commissioners subject to federal oversight.

The language mirrors protections already extended to banks under prior safe-harbor proposals. Insurers would face no federal liability for underwriting property, casualty, liability, or other commercial policies for marijuana operators, provided those operators hold valid state licenses.

Insurance Access Remains a Chokepoint for Operators

Most state-legal cannabis businesses can't secure standard commercial insurance, forcing them to self-insure or rely on specialty carriers charging premiums 3-5 times higher than comparable industries. According to a 2025 National Cannabis Industry Association survey, 62% of operators reported either no general liability coverage or coverage capped below $1 million—far below the $5-10 million standard for retail or manufacturing businesses of similar scale.

The gap stems from federal prohibition. Insurers fear regulatory reprisal or federal money-laundering charges if they're deemed to be facilitating Schedule I drug commerce, even when state law permits the underlying activity. Cultivators face fire risk without property insurance. Dispensaries operate without adequate liability coverage. Product recalls proceed without recall insurance.

Bipartisan Sponsors Signal Banking-Adjacent Strategy

Senators Jeff Merkley (D-OR) and Steve Daines (R-MT) introduced the bill—the same duo behind the SAFER Banking Act that passed the Senate in 2024 but stalled in the House. Merkley's office didn't release bill text or a number as of this writing, but according to a summary circulated to industry groups, the measure is structured as a standalone amendment to the Federal Deposit Insurance Act and the National Bank Act.

This approach sidesteps full descheduling. It doesn't legalize cannabis or alter the Controlled Substances Act. It simply carves out a narrow safe harbor for one category of financial service—insurance underwriting—within the existing Schedule I framework.

The bill is a stopgap, not a solution. It assumes state-legal operators will remain federally illegal for the foreseeable future and tries to patch one of the more dangerous consequences of that split.

Treasury and State Regulators Hold Mixed Positions

The Treasury Department hasn't taken a formal position on insurance safe-harbor legislation, but officials testified in 2025 that existing Bank Secrecy Act guidance could theoretically extend to insurers if they hold client funds or process claims payments. That ambiguity has kept most mainstream carriers out of the sector.

State insurance commissioners are divided. The National Association of Insurance Commissioners issued a 2024 memo stating that state-chartered insurers face no state penalty for covering cannabis businesses, but it acknowledged that federal enforcement risk remains unresolved. California, Colorado, and Oregon have issued explicit guidance encouraging insurers to serve the sector; Texas and Florida have not.

What the Bill Doesn't Cover

The measure doesn't create an affirmative right to insurance, nor does it compel any insurer to underwrite cannabis risks. It removes federal penalties but leaves pricing, underwriting standards, and risk appetite to the market. Insurers remain free to decline cannabis clients for actuarial reasons: high theft rates, fire risk from cultivation equipment, or product-liability exposure from untested edibles.

The bill also doesn't address reinsurance, the wholesale market where primary insurers offload large risks. Most reinsurers are domiciled offshore or operate under international treaties that reference U.S. federal law, and many have blanket exclusions for Schedule I substances. Without reinsurance access, even willing primary carriers face capacity constraints.

Enforcement Uncertainty Will Persist in the Near Term

Even if the bill passes, operators should expect uneven application across states and product types. Hemp-derived cannabinoid insurance—covering delta-8, THCA, or other compounds synthesized from legal hemp—will remain in a separate gray zone, since those products occupy a disputed space between the 2018 Farm Bill and state analog-drug statutes. Carriers will treat hemp-derived intoxicants cautiously until case law or FDA rulemaking settles their status.

For traditional THC cannabis, the bill would provide clarity at the federal level but won't eliminate state-by-state variance. An Oklahoma cultivator and a New Jersey dispensary will still face different underwriting standards based on their state's track record, testing requirements, and recall history.

The next signal: whether the bill receives a committee hearing before the August recess. Merkley's office has indicated it'll push for a floor vote by September, but House passage is uncertain. We'll be watching three indicators—whether the American Bankers Association endorses it, whether the National Association of Mutual Insurance Companies takes a position, and whether any state insurance commissioner testifies in favor.